Bank of Nova Scotia Buys 108,239 Shares of Henry Schein, Inc. $HSIC

Bank of Nova Scotia increased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 1,263.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 116,808 shares of the company’s stock after buying an additional 108,239 shares during the quarter. Bank of Nova Scotia’s holdings in Henry Schein were worth $8,609,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein in the second quarter worth $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC purchased a new position in shares of Henry Schein during the 4th quarter worth approximately $30,000. Federated Hermes Inc. purchased a new position in shares of Henry Schein during the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein in the 4th quarter worth approximately $37,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $85.47 on Monday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $80.98 and a two-hundred day simple moving average of $78.03. The stock has a market capitalization of $9.74 billion, a P/E ratio of 25.82, a PEG ratio of 1.65 and a beta of 0.81. Henry Schein, Inc. has a 52 week low of $61.94 and a 52 week high of $89.34.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Insider Activity

In other news, Director William K. Daniel purchased 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. BMO Capital Markets initiated coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target for the company. Robert W. Baird set a $97.00 target price on Henry Schein in a research note on Wednesday, May 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Citigroup assumed coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target for the company. Finally, UBS Group reiterated a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Henry Schein has an average rating of “Hold” and a consensus target price of $88.62.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.